Indeed, mircera is explicitly contraindicated for patients with chemotherapy‐induced anemia (https://www.mircera.global), limiting EPO‐based ESAs to only a subset of the patients that could otherwise benefit. This evidence concerns the gene EPO and anemia (phenotype).